Real-world effect of bevacizumab and eribulin on metastatic breast cancer using a propensity score matching analysis

Bevacizumab and eribulin are novel agents for the treatment of HER2-negative metastatic breast cancer (MBC); however, the choice between bevacizumab and eribulin for MBC can be difficult. The present study aimed to compare two treatment strategies, eribulin followed by bevacizumab and paclitaxel (BE...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsui, Koshi, Earashi, Mitsuharu, Yoshikawa, Akemi, Fukushima, Wataru, Nozaki, Zensei, Oyama, Kaeko, Maeda, Kiichi, Nakakura, Akiyoshi, Morita, Satoshi, Fujii, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892966/
https://www.ncbi.nlm.nih.gov/pubmed/36761387
http://dx.doi.org/10.3892/mco.2023.2608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892966/
https://www.ncbi.nlm.nih.gov/pubmed/36761387
http://dx.doi.org/10.3892/mco.2023.2608

Ejemplares similares